News and Trends 14 Dec 2022 PrecisionLife to work on R&D with Ono Pharmaceutical PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 PhoreMost and ThinkCyte collaborate on AI-based drug discovery PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 14 Dec 2022 Sibylla Biotech: how physicists met biologists to discover new drugs Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […] December 14, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Vevo Therapeutics launches with $12M to ‘discover better drugs’ Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, has launched with an oversubscribed and upsized $12 million seed financing round. Wing Venture Capital and General Catalyst co-led the round with participation from Mubadala Capital, AIX Ventures, and Camford […] December 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […] November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 18 Nov 2022 How cardioids can usher in the next generation of drug discovery The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […] November 18, 2022 - 6 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 Sensorium closes $30M deal to advance drug discovery engine Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform (BDP). The platform is a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Google and Meta AI could boost cancer research and drug discovery Encoded in the DNA, a protein may be represented as a thread of hundreds of individual molecules called amino acids, linked together. Depending on the particular amino acids combination, a protein folds in a particular way, resulting in a functional 3D shape. The shape makes the function, and with 20 different amino acids available, the […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Optibrium and Lhasa Limited study published on predictive modelling for enzymes A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 First to market doesn’t guarantee success A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 31 Oct 2022 Drug discovery company signs exclusive license to use university’s technology A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […] October 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email